Report Company Directory

PALSOFT INFOSYSTEMS LTD

Paltac Corporation

• Healthcare Handbook 2026 - Building a healthcare and welfare system for the next 100 years: Digital transformation, restructuring, labor shortages by Nomura Research
• ヘルスケアハンドブック2026 - 100年続く医療福祉へ～DX・再編・人手不足 by Nomura Research
• Japan healthcare, medical device, and pharmaceutical (biotech) sector - Jul–Sep results review (results compilation) by Nomura Research
• ヘルスケア・医療機器・医薬品（バイオ） - 7～9月期決算レビュー（決算総集編） by Nomura Research
• PALTAC (8283 JP) (Neutral) - 26/3 Q2 results: Sales and SG&A costs rise on hot weather by Nomura Research
• ＰＡＬＴＡＣ (8283 JP) (Neutral) - Q2決算：猛暑で売上高も販管費も増加 by Nomura Research
• Quick Note - PALTAC (8283 JP) (Neutral) - Takeaways from our tour of the company's Tochigi distribution center by Nomura Research
• Quick Note - ＰＡＬＴＡＣ (8283 JP) (Neutral) - 栃木物流センター見学 Takeaway by Nomura Research
• Quick Note - PALTAC (8283 JP) (Neutral) - Company announces capital and business alliance with Fez by Nomura Research
• Quick Note - ＰＡＬＴＡＣ (8283 JP) (Neutral) - フェズとの資本業務提携を発表 by Nomura Research

PALTALK INC

• Intelligent Protection Management Corp. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 by GlobeNewsWire

Paltek

• Ford Equity International Rating and Forecast Report by Ford Equity Research

PALVELLA THERAPEUTICS INC

• Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas by GlobeNewsWire
• Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve by GlobeNewsWire
• Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update by GlobeNewsWire
• Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference by GlobeNewsWire
• Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies by GlobeNewsWire
• Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025 by GlobeNewsWire
• U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations by GlobeNewsWire
• Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies by GlobeNewsWire
• Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy by GlobeNewsWire
• Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations by GlobeNewsWire